Article
Section 13. Short-course pretransplant antiviral therapy is a feasible and effective strategy to prevent hepatitis C recurrence after liver transplantation in genotype 2 patients.
Transplantation - 27 Apr 2014
Lin Chih-Che, Kabiling Catherine, Chen Chao-Long, Lin Yu-Hung, Liu Yueh-Wei, Wang Chih-Chi, Hu Tsung-Hui, Chiu King-Wah
Abstract excerpt
BACKGROUND: Hepatitis C virus (HCV) recurrence in recipients who are viremic at time of liver transplantation (LT) is universal and carries poor prognosis. Pretransplant antiviral therapy to eradicate HCV reduces recurrence, but withdrawal rate is high. We conducted a short-course (4 weeks) of pegylated interferon alpha-2a (Peg-IFN-α2a) plus ribavirin (RBV) to prevent of HCV recurrence. PATIENTS AND METHODS: From...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.